| Name | Title | Contact Details |
|---|
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
Us Medical Source is a Mount Pleasant, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Precept is a Arden, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs, biologics and vaccines. Unilife has a broad portfolio of injectable drug delivery systems including prefilled syringes, auto-injectors, wearable injectors, drug reconstitution delivery systems, ocular delivery systems and novel devices. Unilife builds long-term partnerships with pharmaceutical and biotechnology companies seeking to leverage our products to enable, enhance and differentiate their injectable therapies. Unilife can develop or customize its device technologies to address the specific drug, commercial and patient needs of its pharmaceutical customers. Unilife’s dynamic business environment, advanced operational capabilities, world-class team and stringent quality processes enables the Company to serve the device innovation needs of its pharmaceutical customers with speed, agility and reliability. A state-of-the-art global headquarters and manufacturing facility in York, PA serves as an integrated center for the seamless design, development, production, quality control, regulatory compliance and commercial supply of its products.